Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 14Thoracic 7Head & Neck 5Genitourinary 5Breast 4Gastrointestinal 3Other solid neoplasm 1Gynecologic 1

Conditions

Ovarian Neoplasms 4Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Turcot syndrome 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Gynecologic Cancers 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 49Nivolumab 22Cyclophosphamide 20fludarabine 13Paclitaxel 9Ipilimumab 9atezolizumab 8aldesleukin 8Specimen Handling 8Interleukin-2 7Carboplatin 7Magnetic Resonance Spectroscopy 6Docetaxel 6Biopsy 6cemiplimab 5fludarabine phosphate 4durvalumab 4Taxes 4Gemcitabine 4Drug Therapy 4spartalizumab 3poly ICLC 3epacadostat 3X-Rays 3Leucovorin 3Injections 3Immunoglobulin G 3Filgrastim 3Cisplatin 3CTLA-4 Antigen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Immune Checkpoint Inhibitors × Gynecologic × Clear all
NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Bolt Biotherapeutics, Inc.

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡